Laboratory of Molecular Immunology, The Rockefeller University, New York, New York, United States of America.
PLoS One. 2011;6(9):e24078. doi: 10.1371/journal.pone.0024078. Epub 2011 Sep 8.
Understanding the antibody response to HIV-1 in humans that show broad neutralizing serologic activity is a crucial step in trying to reproduce such responses by vaccination. Investigating antibodies with cross clade reactivity is particularly important as these antibodies may target conserved epitopes on the HIV envelope gp160 protein. To this end we have used a clade B YU-2 gp140 trimeric antigen and single-cell antibody cloning methods to obtain 189 new anti-gp140 antibodies representing 51 independent B cell clones from the IgG memory B cells of 3 patients infected with HIV-1 clade A or B viruses and exhibiting broad neutralizing serologic activity. Our results support previous findings showing a diverse antibody response to HIV gp140 envelope protein, characterized by differentially expanded B-cell clones producing highly hypermutated antibodies with heterogenous gp140-specificity and neutralizing activity. In addition to their high-affinity binding to the HIV spike, the vast majority of the new anti-gp140 antibodies are also polyreactive. Although none of the new antibodies are as broad or potent as VRC01 or PG9, two clonally-related antibodies isolated from a clade A HIV-1 infected donor, directed against the gp120 variable loop 3, rank in the top 5% of the neutralizers identified in our large collection of 185 unique gp140-specific antibodies in terms of breadth and potency.
了解对具有广泛中和血清学活性的人类 HIV-1 抗体反应是通过疫苗接种来复制这种反应的关键步骤。研究具有跨谱系反应性的抗体尤其重要,因为这些抗体可能针对 HIV 包膜 gp160 蛋白上的保守表位。为此,我们使用了一株 clade B YU-2 gp140 三聚体抗原和单细胞抗体克隆方法,从 3 名感染 HIV-1 clade A 或 B 病毒且具有广泛中和血清学活性的 IgG 记忆 B 细胞中获得了 189 种新的抗 gp140 抗体,代表 51 个独立的 B 细胞克隆。我们的研究结果支持先前的发现,表明对 HIV gp140 包膜蛋白存在多样化的抗体反应,其特征是不同程度扩增的 B 细胞克隆产生高度超突变的抗体,具有异质性的 gp140 特异性和中和活性。除了与 HIV 刺突的高亲和力结合外,绝大多数新的抗 gp140 抗体也是多反应性的。尽管新抗体没有 VRC01 或 PG9 那么广泛或有效,但从一名感染 clade A HIV-1 的供体中分离出的两种与 clonally-related 的抗体,针对 gp120 可变环 3,在我们的 185 种独特的 gp140 特异性抗体中,在广度和效力方面,排名前 5%。